Perspectives on antiviral use during pandemic influenza.

Antiviral agents could potentially play a major role in the initial response to pandemic influenza, particularly with the likelihood that an effective vaccine is unavailable, by reducing morbidity and mortality. The M2 inhibitors are partially effective for chemoprophylaxis of pandemic influenza and evidence from studies of interpandemic influenza indicate that the neuraminidase inhibitors would be effective in prevention. In addition to the symptom benefit observed with M2 inhibitor treatment, early therapeutic use of neuraminidase inhibitors has been shown to reduce the risk of lower respiratory complications. Clinical pharmacology and adverse drug effect profiles indicate that the neuraminidase inhibitors and rimantadine are preferable to amantadine with regard to the need for individual prescribing and tolerance monitoring. Transmission of drug-resistant virus could substantially limit the effectiveness of M2 inhibitors and the possibility exists for primary M2 inhibitor resistance in a pandemic strain. The frequency of resistance emergence is lower with neuraminidase inhibitors and mathematical modelling studies indicate that the reduced transmissibility of drug-resistant virus observed with neuraminidase inhibitor-resistant variants would lead to negligible community spread of such variants. Thus, there are antiviral drugs currently available that hold considerable promise for response to pandemic influenza before a vaccine is available, although considerable work remains in realizing this potential. Markedly increasing the quantity of available antiviral agents through mechanisms such as stockpiling, educating health care providers and the public and developing effective means of rapid distribution to those in need are essential in developing an effective response, but remain currently unresolved problems.

[1]  F. Hayden Antivirals for pandemic influenza. , 1997, The Journal of infectious diseases.

[2]  H. Maeda,et al.  Isolation of Amantadine-Resistant Influenza A Viruses (H3N2) from Patients following Administration of Amantadine in Japan , 2001, Journal of Clinical Microbiology.

[3]  A. Monto,et al.  Prevention of Russian influenza by amantadine. , 1979, JAMA.

[4]  J. Oxford,et al.  Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. , 1969, Bulletin of the World Health Organization.

[5]  J. McKimm-Breschkin,et al.  Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.

[6]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[7]  A. Osterhaus,et al.  Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy Studies , 2000, Antimicrobial Agents and Chemotherapy.

[8]  A S Perelson,et al.  Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. , 1998, The Journal of infectious diseases.

[9]  R. Couch,et al.  Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza. , 1981, Antiviral research.

[10]  P. Ward,et al.  Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.

[11]  R. Pettersson,et al.  Protection of Man from Natural Infection with Influenza A2 Hong Kong Virus by Amantadine: A Controlled Field Trial , 1970, British medical journal.

[12]  F. Hayden,et al.  Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. , 2000, Archives of internal medicine.

[13]  P Diggory,et al.  Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial , 2001, BMJ : British Medical Journal.

[14]  F. Hayden,et al.  Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. , 1989, The New England journal of medicine.

[15]  C. Hall,et al.  Children with influenza A infection: treatment with rimantadine. , 1987, Pediatrics.

[16]  W. J. Bean,et al.  Biologic potential of amantadine-resistant influenza A virus in an avian model. , 1989, The Journal of infectious diseases.

[17]  S. Trottier,et al.  Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. , 2000, The Journal of infectious diseases.

[18]  M. Meltzer,et al.  The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.

[19]  R. Douglas,et al.  Amantadine therapy of epidemic influenza A2-Hong Kong. , 1970, Antimicrobial agents and chemotherapy.

[20]  F. Hayden,et al.  Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. , 1997, The Journal of infectious diseases.

[21]  R. Pettersson,et al.  Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients. , 1980, The Journal of infectious diseases.

[22]  N. Cox,et al.  Low incidence of rimantadine resistance in field isolates of influenza A viruses. , 1999, The Journal of infectious diseases.

[23]  P. Ward,et al.  Long‐Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population , 2001, Journal of the American Geriatrics Society.

[24]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[25]  A. Monto,et al.  Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. , 2000, The New England journal of medicine.

[26]  A. Nafziger,et al.  Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. , 2000, Archives of internal medicine.

[27]  J. Oxford,et al.  Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. , 2001, JAMA.

[28]  J. Oxford,et al.  Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A 2 -Hong Kong infection. A controlled double-blind study. , 1971, Lancet.

[29]  A. Monto,et al.  Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. , 1999, JAMA.

[30]  A. Monto,et al.  Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. , 1999, The Journal of antimicrobial chemotherapy.

[31]  N. Cox,et al.  Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  P. Ward,et al.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.

[33]  K. Murphy,et al.  Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease , 2000 .

[34]  F. Hayden,et al.  Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. , 1998, The Journal of infectious diseases.

[35]  A. A. Smorodintsev,et al.  The prophylactic effectiveness of amantadine hydrochloride in an epidemic of Hong Kong influenza in Leningrad in 1969. , 1970, Bulletin of the World Health Organization.

[36]  A. Monto,et al.  Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. , 2002, Antiviral research.

[37]  R. Webster,et al.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. , 1998, The Journal of infectious diseases.

[38]  E. Birt,et al.  Administration of amantadine for the prevention of Hong Kong influenza. , 1970, Bulletin of the World Health Organization.

[39]  M. Schoch-Spana Implications of pandemic influenza for bioterrorism response. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  M Tisdale,et al.  Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors , 2000, Reviews in medical virology.